SUBSTITUTE (MODIFIED)	FORM A	<b>60</b>	444	9					.S. DEPARTM ATENT AND			CMC/	. DOCKET N 161	0.	SERIA 10/752	
(景)	, L		2				•		OSURE LICANT				ICANT Elliot Rothenl	perg et		
(37 CFR 1.98)	B) RADE	MAR	Se Se	e se	vera	al sh	eet	s if n	ecessary)				G DATE ry 7, 2004		GROL Unkno	
									U.S.	PATENT	DOCUMENTS				<u>.</u>	
EXAMINER INITIAL			PA'	TEN	IT N	IUM	BEI	R	ISSUE DATE		PATENTEE		CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE
M	A.A	5	8	7	1	7	2	3	02/16/99	Strieter	et al.		424	85.1		06/O6/1995
	A.B													<u> </u>		
	A.C													ļ		
	A.D						L							ļ		
	A.E				_		L	L		ļ	<del> </del>					
	A.F				L		L			ļ			ļ			ļ
	A.G	$oxed{igspace}$			L		L		,	·				<u> </u>		
	A.H	_			L		L	_					<u> </u>	<u> </u>		ļ
	A.I	_	L		L		L	<u> </u>	ļ	<u> </u>				<del> </del>		
	A.J	$\perp$	L		L	L	L	<u> </u>						ļ		
	A.K		<u> </u>					L		<u></u>			<u> </u>			1
					FC	RE	IGN	I PAT	ENTS OR PL	JBLISHED	FOREIGN PA	TENT A	APPLICATION	NS		
				CUI				P	PUBLICATION DATE		COUNTRY OF		CLASS	SUBCL	ASS	TRANSLATION (YES/NO)
M	A.L	w	2016	<b>522</b> 7	74			08	/O3/2001	PCT	- Spain		A61K	38/19		Abstract only
	A.M	W	<b>)</b> 942	2127	77			09	/29/2004	PCT	- US		A61K	37/02		N/A
re .	A.N	W	<b>D94</b> (	0467	70			03/	/O3/1994	PCT	- US		C12N	15/O0		N/A
	A.O									_						
	A.P							$oldsymbol{ol}}}}}}}}}}}}}}}}}}$		·						
	A.Q							上					<u> </u>	<u> </u>		
					<u> </u>	тн	ER	DOC	UMENTS (Inc	luding Au	thor, Title, Date	e, Place	of Publicatio	n)		
M	A.R										000199, dated					
1	A.S							nes, ( 4299		eceptors a	ind Allergy, Inte	emation	al Archives of	Allergy a	nd Immi	unology 124(4):423-
AL	A.T	Me Mo	doff	B e	t al.	., <u>IF</u> of A	N-y	-Indu ma, 1	cible Protein 1 The Journal of	10 (CXCL	10) Contributes plogy 168(10):5	to Airw 278-528	ay Hyperread 37 (2002), XP	tivity and 00228990	Airway I	nflammation in a
EXAMINER					M	1					DATE CONS	SIDERE	1/17/0	6		
EXAMINER: I	nitial if ci	tatio	n cc	nsic	dere	ed, w	vhet	her c	or not in confor	rmance. I	Draw line throu	gh citati	on only if not	in conform	nance <u>a</u>	nd not considered.

7																	
SÚBŠTITUTI (MODIFIED)	E FORM F		\ <del>.</del>	-00	MA	TIOI	N DI	P/	S. DEPART ATENT AND OSURE	MENT TRA	T OF COMM DEMARK C	MERCE OFFICE	CMC/1	CANT		SERIA 10/752	
₹ SE	<b>D</b> 1	٠	βT	ATE	ME	NT	BY A	\PPI	LICANT				Mark E al.	Elliot Rothent	erg et		
(37 CFX 39	2.0 200	74 E	3) (V) Se	e se	vera	i sh	eets	if ne	ecessary)				FILING	B DATE ny 7, 2004		GROU Unkno	
(0.0.1)	DEMARK				-				U.S	 . PAT	ENT DOCU	JMENTS		· · · · · · · · · · · · · · · · · · ·			
EXAMINER INITIAL		Ī	PA <sup>-</sup>	TEN	T N	UM	BER		ISSUE DATE		PAT	ENTEE		CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE
	B.A	1															
	B.B		П							$\top$							
	B.C	T	П							T							
	B.D	1			•												
	B.E	1								1							
	B.F								-	$\top$							
	B.G									T		· · · · · · · · · · · · · · · · · · ·					
	В.Н																
	B.I																
	B.J																
	B.K								,								
					FO	RE	GN	PAT	ENTS OR P	UBLK	SHED FOR	EIGN PA	TENT A	PPLICATIO	NS		
					MEN BER			PI	UBLICATION DATE	N		NTRY O		CLASS	SUBCI	.ASS	TRANSLATION (YES/NO)
	B.L																
	B.M																
	B.N																
	B.O																
	В.Р							,	,								•
	B.Q																
					0	THE	ER D	ocu	JMENTS (In	cludin	ng Author, 1	Title, Date	e, Place	of Publication	٦)		
Re	B.R		adar 97)	i C	et al	I., <u>M</u>	lig, t	ne M	lonokine Ind	uced I	by Interfero	on-y, Pror	notes Tu	ımor Necrosi	s in Vivo,	Blood 89	9 (8):2635-2643
Me Me	B.S	Th 16	oma (4):A	s M	S et	al.,	Role	e of 1	P-10 in a Co 34300, Abs	ockroa tract 2	ach Antiger 245.3	n Induced	Muring	Model of Ain	vay Hype	reactivit	y, FASEB Journal
<del> </del>	B.T																

1/27/06

**EXAMINER** 

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

DATE CONSIDERED

: <b>s</b> ,												Shee	t_1 (A) of 11
SUBSTITUTE MODIFIED)		TO-144	9					NT OF COMMERCE RADEMARK OFFICE		Y. DOCKET N	0.	SERIA 10/752	L NO.
MAY 10	2004 J						OSURE LICANT			PLICANT k Elliot Rothen	berg et		
(3) OF ROSE	BEST CERT	(Us	e se	vera	l shee	ts if n	ecessary)			NG DATE Jary 7, 2004		GROU Unkno	
							U.S. PA	ATENT DOCUMENTS					
EXAMINER INITIAL		PA	TEN	NT N	UMBE	R	ISSUE DATE	PATENTEE		CLASS	SUBC	CLASS	FILING DATE IF APPROPRIATE
	A.A										_		
	A.B			Ц									
	A.C										ļ		
	A.D	$oxed{oxed}$											
	A.E							. <u>.</u>					
	A.F												
	A.G										<u> </u>		
	A.H										ļ		
	A.I												
	A.J												
	A.K												
				FO	REIGI	N PAT	ENTS OR PUB	LISHED FOREIGN PA	TENT	APPLICATION	NS.		
		DC	OCU	MEN BER	T	P	UBLICATION DATE	COUNTRY OF		CLASS	SUBCI	_ASS	TRANSLATION (YES/NO)
	A.L												
	A.M												
	A.N												
	A.O												
	A.P												
	A.Q												
				0	THER	DOC	UMENTS (Includ	ding Author, Title, Date	e, Plac	e of Publication	n)		

A.R Combadiere et al., Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor, J. Bio. Chem. 270:16491-16494 (1995) and 271:11034 (1996)

A.S Daugherty et al., Cloning, Expression, and Characterization of the Human Eosinophil Eotaxin Receptor, J. Exp. Med. 183:2349-2354 (1996)

A.T Forssmann et al., Eotaxin-2, a Novel CC Chemokine that is Selective for the Chemokine Receptor CCR3, and Acts Like Eotaxin on Human Eosinophil and Basophil Leukocytes, J. Exp. Med. 185:2171-2176 (1997)

**EXAMINER** 

M

DATE CONSIDERED

1/17/06

•														<u> </u>	Shee	1 2 (B) of 11
SUBSTITUTI (MODIFIED)		PTO-1	449							OF COMMERCE DEMARK OFFICE		ATTY.	DOCKET NO	). 	SERIA 10/752	
								OSURE LICANT				APPLIC Mark E al.	CANT lliot Rothenb	erg et		
(37 CFR 1.98	B(b))	(	Use s	ever	al sh	neets	if ne	cessary)				FILING Januar	DATE 7, 2004		GROU Unkno	
								U.S.	PATE	ENT DOCUMENTS	}					
EXAMINER INITIAL			PATE	NT I	NUM	BER		ISSUE DATE		PATENTEE			CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE
	B.A															
	В.В					$\bigsqcup$								ļ		
	B.C												_			
	B.D															
	B.E															
	B.F				Π											
	B.G	П														
	в.н			T	T											
	B.I															
	B.J	П		Τ	Τ											
	В.К															
				F	ORE	IGN	PAT	ENTS OR P	UBLIS	SHED FOREIGN PA	ΆΊ	TENT A	PPLICATION	15		
			DOC NU	UME MBE			PI	UBLICATION DATE	7	COUNTRY O			CLASS	SUBCI	_ASS	TRANSLATION (YES/NO)
	B.L.															
	В.М							,								
	B.N															
<del></del>	B.O								$\neg$							
	B.P															
	B.Q		-								_					
		•		(	отн	ER (	ocu	JMENTS (In	cludin	ng Author, Title, Dat	te,	, Place o	of Publication	۱)		
M	B.R	Ger 7:8	ter e 36-84	t al.,	<u>Fun</u> 997)	ction	al ex	pression of	the eo	otaxin receptor CCR	₹3	in T lym	phocytes co	-localizin	g with ed	osinophils, Curr. Biol.
1	B.S	He	ath et	al., (	Cher	noki	ne Re	ceptor Usa	ge by	Human Eosinophils	<u>s</u> ,	J. Clin.	nvest. 99:17	'8-184 <b>(1</b>	997)	

B.S Heath et al., Chemokine Receptor Usage by Human Eosinophils, J. Clin. Invest. 99:178-184 (1997)

B.T Jinquan et al., CXCR3 Expression and Activation of Eosinophils: Role of IFN-q-Inducible Protein-10 and Monokine Induced by IFN-q, J. Immunol. 165:1548-56 (2000)

EXAMINER

DATE CONSIDERED

•															Sheet	3 (C) of 11
SUBSTITUTE (MODIFIED)	FORM P	TO-14	149								MMERCE K OFFICE	ATTY CMC/	DOCKET NO	<b>).</b> .	SERIA 10/752	
								OSURE ICANT					ICANT Elliot Rothenb	erg et		
(37 CFR 1.98(	h))	(U	se se	evera	al sh	eets	if ne	cessary)	)				G DATE bry 7, 2004		GROU! Unknow	
(37 CFK 1.90)	<u> </u>								IS PAT	FNT DO	CUMENTS					
EXAMINER	<u> </u>	Γ.	ATE	AIT A	11 1841	050		ISSU	E		ATENTEE		CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE
INITIAL	C.A	╁	T	T	TOWN			DATE			ATENTEE		05.00			
	C.A	$\vdash$	┿	+	Н	$\dashv$								-		
	C.C	$\vdash$	╁	十	Н				_		<del></del>					
	C.D	$\vdash$	╁	╁	Н		,						+	_		
	C.E	H	+	╁	$\vdash$	Н			_	<del></del>		<del></del>		<u> </u>		
·	C.F	${\rm H}$	╁	╁	Н	$\vdash$			-				<del></del>	<del> </del>		
·	C.G	H	╁	$\dagger$		Н								ļ		
	C.H	††	+	+	$\vdash$	H								1		
	C.I	††	$\dagger$	$\dagger$	П	Н		•			· · · · · · · · · · · · · · · · · · ·				-	
	C.J	ff	十	十	$\vdash$	Н									<u> </u>	
	C.K	${}^{\dag}$	$\top$	T		Н						·				
	1			FC	ORE	IGN	PAT	ENTS O	R PUBLI	SHED F	OREIGN PA	TENT /	APPLICATION	NS		
		C	OOCL NUM				P	UBLICAT DATE			OUNTRY O		CLASS	SUBCI	_ASS	TRANSLATION (YES/NO)
	C.L							-								
	C.M															
	C.N															
	C.O										•			L		
	C.P							<u> </u>								
	C.Q												<u> </u>	_		
													of Publicatio		<u>-</u> -	····
M	C.R	Kitau Chei	ıra et mokir	al., ne R	Mole ecer	cula otor	ar Clo 3, J. I	oning of a Biol. Che	a Novel I em. 274:2	Human C 27975-80	C Chemoki (1999)	ne (Eota	xin-3) That Is	a Functi	onal Liga	and of CC
1	C.S	Loet Biol.	scher Cher	reta m. 2	al., <u>T</u> 76:2	he L 986	igan -91 (2	ds of CX 2001)	C Chemo	okine Re	ceptor 3, I-T	AC, Mic	g, and IP10, A	ve Natura	al Antago	nists for CCR3, J.
M	C.T	Luka	ics, <u>F</u>	Role	of C	hem	okine	s in the	Pathoge	nesis of	Asthma, Na	tue Rev	, Immunol. 1:	108-16 (2	001)	<u>.                                      </u>
EXAMINER		140	1								DATE CONS	SIDERE	1/17/	06		

	Sheet 4 (D) of 11
ATTY. DOCKET NO. CMC/161	SERIAL NO. 10/752,659
APPLICANT Mark Elliot Rothenberg et	

**SUBSTITUTE FORM PTO-1449** (MODIFIED)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

FILING DATE January 7, 2004 **GROUP** Unknown

(37 CFR 1.98(b))

								U.S. F	PATENT DOCUMENTS			
EXAMINER INITIAL			PA	TENT	ΓN	JMBI	ER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D.A											
	D.B											
	D.C											
	D.D											
	D.E											
	D.F											
	D.G											
	D.H											
	D.I											
	D.J										<u> </u>	
	D.K											
					FOF	REIG	N PA	TENTS OR PU	BLISHED FOREIGN PATEN	T APPLICATION	vs	
-				CUMB		Τ		PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	D.L											
	D.M											
-	D.N											
	D.O											
	D.P											
	D.Q											
					01	THEF	DO	CUMENTS (Incl	uding Author, Title, Date, Pla	ce of Publication	n)	
M	D.R	Lu	ster,	Che	mok	ines	- Ch	emotactic Cytok	ines That Mediate Inflammati	on, N. Eng. J. N	Med. 338:436-445	(1998)
	D.S	Ma (19	itthe 98)	ws el	al.,	Eot	axin i	s required for the	e baseline level of tissue eosi	nophils, Proc. N	lati. Acad. Sci. U.	S.A. 95:6273-78
il	D.T	Mi (20	ishra 101)	et a	I., <u>A</u>	n eti	ologic	cal role for aeroa	allergens and eosinophils in e	xperimental esc	pphagitis, J. Clin. I	nvest. 107:83-90

**EXAMINER** 

**DATE CONSIDERED** 

Sheet 5 (E) of 11

SUBSTITUTE (MODIFIED)	FORM P	TO-1	449	•							COMMERCE ARK OFFICE	ATTY.	DOCKET NO	).	SERIA 10/752	
								OSUF				APPLIO Mark E al.	CANT Iliot Rothenb	erg et		
		(1	Use	sev	era!	l shee	ts if n	ecessa	ary)			FILING			GROU	
(37 CFR 1.98(	b))						·	_				Januar	y 7, 2004		Unknov	wn
								1	U.S. I	PATENT [	DOCUMENTS			r		
EXAMINER INITIAL			PAT	EN	T NI	UMBE	R		SUE ATE		PATENTEE		CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE
	E.A					$\bot$	$oxed{}$	<u> </u>								
	E.B													ļ		
	E.C					$\perp$										
	E.D															
	E.E															
	E.F													_		
	E.G															
	E.H															
	E.I	$\prod$														
	E.J	П														
	E.K	П														
					FO	REIG	N PAT	TENTS	OR PU	BLISHED	FOREIGN PA	ATENT A	PPLICATION	18		
				CUI			F		CATION		COUNTRY O		CLASS	SUBC	LASS	TRANSLATION (YES/NO)
	E.L							•								
	E.M							_								
	E.N															
	E.O															
	E.P															
	E.Q															
					0	THEF	DOC	UMEN	ITS (Inc	duding Aut	thor, Title, Dat	e, Place o	of Publication	1)		
M	E.R	Nid	kel (	et al	., <u>c</u>	hemo	kines	and al	lergic di	sease, J. /	Allergy Clin. In	nmunol.	104:723-742	(1999)		
1	E.S	Pat Clas	el e sse	t al. s of	My	lecula eloid F	or and Proger	Funct	ional Ch J. Exp. l	naracteriza Med. 185:	ation of Two No 1163-1172 (19	ovel Hum 997)	an C-C Cher	nokines a	as Inhibit	ors of Two Distinct
M	E.T	Por J. E	ath xp.	et a	al., <u>N</u> d. 1	Molec 83:24	ular C 37-24	loning 48 (19	and Cha	aracterizat	tion of a Huma	ın Eotaxir	Receptor E	xpressed	Selectiv	ely on Eosinophils,
EXAMINER		H	1								DATE CON	SIDERED	//	117/0	06	
EVANINES	nitial if o	tation		neid	ore	d wh	ther o	or not i	n confo	mance [	Oraw line throu	oh citatio	n only if not	in confor	mance a	nd not considered.

															Sheet	6 (F) of 11
SUBSTITUTE (MODIFIED)	FORM F	PTO-1	449	3		•			S. DEPARTM			ATTY. CMC/1	DOCKET NO	Ο.	SERIA 10/752	
									OSURE LICANT			APPLIC Mark E al.	CANT Illiot Rothenb	erg et		
(37 CFR 1.98)	(b))	(1	Use	sev	veral	she	ets i	if ne	cessary)				DATE y 7, 2004		GROU! Unknow	
									U.S.	PATENT I	DOCUMENTS					
EXAMINER INITIAL			PAT	ΓEΝ	TNU	JMB	BER		ISSUE DATE		PATENTEE		CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE
	F.A	П														
	F.B	$\sqcap$					Î									
	F.C		$\exists$				T									
	F.D	П												<u> </u>		
	F.E	$\prod$												<u> </u>	·····	
	F.F	П												<u> </u>		
	F.G	$\prod$											<u></u>			
	F.H	П														
	F.I															
	F.J															
	F.K															
					FO	REIG	GN F	PATI	ENTS OR PL	BLISHED	FOREIGN PA	TENT A	PPLICATION	NS .	·	
					MEN BER	T		Pl	UBLICATION DATE		COUNTRY OF		CLASS	SUBCL	ASS	TRANSLATION (YES/NO)
	F.L															
	F.M															
	F.N						_									
	F.O						$\perp$									
	F.P						$\bot$				···		_			
	F.Q						$\perp$					]				
					01	ГНЕ	R D	OCL	JMENTS (Inc	luding Au	thor, Title, Date	e, Place	of Publication	n)		
M	F.R	Clin	ı. Im	ımu	nol.	108	:594	-601	(2001)							nism, J. Allergy
	F.S	Pov	vere	et al	1., <u>Tr</u>	ne c	hem	okin	e system: no	vel broad-	spectrum thera	apeutic ta	argets, Curr.	Opin. Pha	armacol.	1:417-24 (2001)
M	F.T	Rol	lins,	Ch	emo	kine	<u>s</u> , B	lood	90:909-928	(1997)						
EXAMINER	19	4									DATE CONS	SIDERED	1/17	106		,

Sheet 7 (G) of 11

SUBSTITUTE (MODIFIED)	FORM P	TO-14	149				U. Pi	S. DEPA	RTMEN	T OF CO	OMMERCE RK OFFICE	ATTY. CMC/1	DOCKET NO	). 	SERIA 10/752	
		11	NF( STA	ORM. TEM	ATIO ENT	N D	ISCL APPI	OSURE				APPLIO Mark E al.	CANT Illiot Rothenb	erg et		
(37 CFR 1.98(	b))	(U	lse :	seve	ral sl	neets	s if ne	ecessary)	)				DATE by 7, 2004		GROU Unkno	
								ι	J.S. PAT	TENT D	OCUMENTS					-
EXAMINER INITIAL		P	ATI	ENT	NUM	IBEF	₹ .	ISSU DATE			PATENTEE		CLASS	SUBC	CLASS	FILING DATE IF APPROPRIATE
	G.A															
	G.B															
	G.C															
	G.D														<del></del>	
	G.E												<b> </b>			
	G.F				$\perp$				·							
	G.G						<u> </u>						ļ	ļ <u>.</u>		
	G.H					$oldsymbol{ol}}}}}}}}}}}}}}$					<u></u>		<u> </u>			
	G.I			$\perp$						<u> </u>						
-	G.J					L								<u> </u>		
	G.K							<u> </u>						<u> </u>		
				F	ORE	IGN	PAT	ENTS O	R PUBL	ISHED	FOREIGN PA	ATENT A	PPLICATION	<b>1</b> S		
		(		JMBE			Р	UBLICAT DATE			COUNTRY O		CLASS	SUBC	LASS	TRANSLATION (YES/NO)
	G.L						<u> </u>									
	G.M						<u> </u>									
	G.N						<u> </u>									
	G.O						<u> </u>					<del></del>				
	G.P						_							<u>.</u>		
	G.Q						<u>L</u> _		<del></del>	1	<del></del>		<u> </u>			
													of Publication			
M	G.R	tum	or s	uppr	essio	<u>n,</u> P	roc. 1	Natl. Acad	d. Sci. 9	2:8960-8	8964 (1995)					terleukin 4-induced
1	G.S	Roti Puin	neni non	berg ary E	et al.	, <u>Eo</u> ophi	taxin lia in	Triggers the Prese	Eosinop ence of l	hil-Sele Interleuk	ctive Chemo kin 5 in Mice,	taxis and Molecula	l Calcium Flu ar Medicine 2	x via a D :334-348	istinct Re I (1996)	eceptor and Induces
1/st	G.T	Rotl 21:2	nenl 191-	berg 295 (	, <u>Eot</u>	axin:	An E	Essential	Mediato	or of Eos	inophil Traffi	cking into	o Mucosal Tis	ssues, Ar	n. J. Res	spir. Cell Mol. Biol.
EXAMINER		1				-					DATE CON	SIDERE	1/17/	106		
EXAMINER: Include a cop	Initial if c	itation	cor	nside next	red,	whe	ther o	or not in c	conforma	ance. D	raw line throu	ıgh citati	on only if not	in confor	mance <u>a</u>	and not considered.

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE (MODIFIED)	FORM F	TO-1	449	)			U. P	S. DEPARTA	MENT OF (	COMMERCE ARK OFFICE	ATTY. CMC/1	DOCKET NO	).	SERIA 10/752	
·			INF ST	ORM	IATI IEN	ON D IT BY	ISCL APPI	OSURE LICANT			APPLION Mark E	CANT Illiot Rothenb	erg et		
(37 CFR 1.98)	(b))	. (	Use	seve	eral	sheet	s if ne	ecessary)				DATE y 7, 2004		GROU Unkno	
								U.S.	PATENT (	DOCUMENTS					
EXAMINER INITIAL			PAT	rent	NU	MBEI	₹	ISSUE DATE		PATENTEE		CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE
	H.A									_					
	н.в	П			T										
· · · · · · · · · · · · · · · · · · ·	H.C	П			T					<u> </u>					
	H.D				1										
	H.E				1										
	H.F	П			1										
	H.G														
******	н.н														
	H.1														
	H.J										_				
	н.к										<u>-</u>				
				1	FOF	REIGN	PAT	ENTS OR P	JBLISHED	FOREIGN PA	ATENT A	PPLICATION	IS		
			_	CUM		Γ	Р	UBLICATION DATE		COUNTRY OF		CLASS	SUBCI	_ASS	TRANSLATION (YES/NO)
	H.L														
	н.м			,									<u></u>		
	H.N														
	н.о														
	н.Р														
	H.Q			_			_								
					ОТ	HER	DOC	UMENTS (Inc	luding Au	thor, Title, Date	e, Place	of Publication	1)		
PL	H.R						_			92-1600 (1998					
	H.S	Roi Me	hen d. 1	berg, 85:78	<u>Ta</u> 5-7	rgeted 90 (19	1 <u>Disr</u> 97)	uption of the	Chemokin	e Eotaxin Part	ially Redu	uces Antigen	-induced	Tissue E	osinophilia, J. Exp.
TH.	н.т	Sal (19		o et a	ıl., <u>S</u>	Select	ve E	xpression of t	he Eotaxin	Receptor CC	R3 by Hu	man T Helpe	er 2 Cells,	Science	277:2005-2007
EXAMINER		Pro	1							DATE CONS	SIDEREC		17/0	6	
EXAMINER:	Initial if c	itatio	n co with	nside next	red	, whei	her o	or not in confo	mance. (	Draw line throu	gh citatio	on only if not	in conform	mance <u>a</u>	nd not considered.

Sheet 9 (I) of 11

SUBSTITUTE (MODIFIED)	FORM P	TO-	144!	9									COMME ARK OF			ATTY. CMC/1		KET N	O		SERI/ 10/75		•	
									OSUF LICAN						1	APPLIC Mark E al.			berg e	et				
(37 CFR 1.98(	b))	(	Use	9 S8\	/era	l she	ets	if ne	ecess	ary)						FILING Januar					GROU Unkno			
	-									U.S.	PAT	ENT (	DOCUM	ENTS	;									
EXAMINER INITIAL			PA <sup>-</sup>	TEN	ΤN	UMB	ER		_	SUE			PATE	ITEE			С	LASS	S	UBC	LASS		FILING DA	
	I.A																	,	<u> </u>					
	I.B																						······································	
	I.C																					<u> </u>		
	I.D																					ļ		
	I.E																_					$oldsymbol{ol}}}}}}}}}}}}}}}}}$		
	I.F																L		ļ			$oldsymbol{oldsymbol{\perp}}$		
	I.G													L.		<u> </u>			<u> </u>					
	t.H																					<u> </u>		
	1.H																		↓_			_		
	I.J										ļ						_		_			_		
	I.K																		<u></u>					
					FO	REI	3N	PAT	ENTS	S OR P	UBLI	SHED	FORE	GN PA	A٦	ENT A	PPLI	CATIO	NS					
				CUN				P		CATION ATE	N		COUNT				CL	ASS	śu	BCI	_ASS	TF	(YES/NO	
	I.L																							
	1.M																		ļ					
	I.N						$\bot$												ļ .					
	1.0										_										<del></del>	ļ		
	I.P																		<u> </u>					
	I.Q																		<u>L</u>					
													thor, Titl		_									
M	I.R	Shi Ext	nka iibit	i et a s Po	al., <u>(</u> oten	A No t Acti	vel vity	Hum Tov	nan C vard f	C Cher Eosinor	nokin ohils,	e, Eol	taxin-3, nunol. 1	Which 63:160	1 <u>1:</u> 02	s Expre -1610 (	ssed 1999	in IL-4 ))	-Stimu	ulate	d Vasc	ılar Er	dothelia	Cells,
	I.S					<u>Char</u> 999)		eriza	tion c	of CCR3	3 Ехр	ressio	on on Hu	man A	Air	way Ep	ithel	al Cell	<u>s,</u> J. A	llerg	y Clin. I	mmun	ol. 103 (i	No. 1
the	I.T	Ugi <u>Eot</u>	ucci	oni e	et a CP-	l., <u>Hi</u> 4, an	gh E	xpre	essio	n of the mokine	<u>Cher</u> <u>s</u> , J. (	mokin Clin. Ir	e Receptivest. 1	tor C0	<u>CF</u>	R3 in Hu -1143 (	<u>ıman</u> 1997	Blood )	Baso	ohils	Role in	Activa	ation by	<u>-</u>
EXAMINER		,	B	1									DATE	CONS	SII	DERED	)	//	117	10	6			
EXAMINER: I	nitial if ci y of this f	tation	n co with	nsid	lere	d, wt	neth unic	er o	r not i	in confo	ormar nt.	ice. E	Oraw line	throu	Jg	h citatio	n on	ly if not	in co	nforr	mance <u>a</u>	ind no	t conside	red.

Sheet 10 (J) of 11

INFORMATION DISCLOSURE STATEMENT BY APPLICANT MAR. Elical Robenberg et al.  (Use several sheets if necessary)  IU.S. PATENT DOCUMENTS  U.S. PATENT DOCUMENTS  U.S. PATENT DOCUMENTS  U.S. PATENT DOCUMENTS  EXAMINER  PATENT NUMBER  ISSUE  DATE  PATENTEE  CLASS  SUBCLASS  FLING DATE  F	SUBSTITUTE FORM PTO-1449  (MODIFIED)  U.S. DEPARTMENT OF PATENT AND TRADEM												ATTY. CMC/1	DOCKET NO	). 	SERIAL NO. 10/752,659			
UNITIAL  PATENT NUMBER  PATENT NUMBER  US. PATENTE  CLASS SUBCLASS  FAUNG DATE  PATENTEE  CLASS SUBCLASS  FAUNG DATE  PATENTEE  CLASS SUBCLASS  FAUNG DATE  PATENTEE  LASS SUBCLASS  FAUNG DATE  PATENTEE  CLASS SUBCLASS  TRANSLATION  (YES/NO)  JL  JM  JN  JN  JN  JN  JN  JN  JN  JN  JN										Mark E		erg et							
EXAMINER    PATENT NUMBER   ISSUE   PATENTEE   CLASS   SUBCLASS   FILING DATE   FAPROPRIATE	(37 CFR 1.98)	Use	sev	era	l she	ets	if ne	ecessary)											
PATENT NUMBER  DATE  PATENTEE  CLASS SUBCLASS IF APPROPRIATE  J.B.  J.B.  J.C.  J.D.  J.D.  J.E.  J.J.  J.F.  J.J.  J.M.  J.N.  J.N.  J.N.  J.D.  OTHER DOCUMENTS (Including Author, Title, Date, Piace of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Piace of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Piace of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Piace of Publication)  J.D.  J.										U.S.	PATENT I	DOCUMENTS							
J.B.  J.C.  J.D.  J.D.  J.E.  J.F.  J.F.  J.G.  J.H.  J.J.  J.M.  J.D.  J.M.  J.D.			PATENT NUMBER									PATENTEE	CLASS		SUBCLASS				
J.C.  J.D.  J.E.  J.F.  J.F.  J.F.  J.G.  J.H.  J.J.  J.S.  Zhang et al., Differential Effects of Leukotactin-1: And Macrophage Inflammatory Protein-1alpha on Neutrophilis Mediated by CCR1. J. Immunol. 162:4930-4932 (1999)  D.J.  J.T.  J.T.  J.T.  J.J.  DATE CONSIDERED  DATE CONSIDERED		J.A																	
J.D.  J.F.  J.F.  J.F.  J.G.  J.H.  J.H.  J.J.  J.S.  Zhang et al., Differential Effects of Leukotactin-1: Al Novel Human beta-Chemokine, a Chemoaltractant for Neutrophils, Monocydes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205  J.J.  J.S.  Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1, J. Immunol. 162:4930-4932 (1999)  DATE CONSIDERED  J.J.7.  DATE CONSIDERED  J.J.7.  J.J.J.  J.J.7.  J.J.7.  J.J.J.  J.J.7.  J		J.B							-					l					
J.E.  J.F.  J.G.  J.H.  J.J.  J.J.  J.J.  J.J.  J.J.  J.J.  J.J.  J.J.  DOCUMENT NUMBER  DOCUMENT NUMBER  PUBLICATION COUNTRY OR PATENT APPLICATIONS  CLASS SUBCLASS TRANSLATION (YES/NO)  J.L.  J.M.  J.N.  J.N.  J.D.  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  Woncoytes, and Lymphocytes, and a Potent Agonist at CC Chemokine, a Chemoattractant for Neutrophils, (1997)  J.S.  Zhang et al., Differential Effects of Leukolactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CRRI. J. Immunol. 152:4938-4942 (1999)  EXAMINER  DATE CONSIDERED  JATE CONS		J.C						•											
J.F.  J.G.  J.H.  J.H.  J.J.  J.J.  J.J.  J.J.  J.J.  J.J.  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  PUBLICATION COUNTRY OR PATENT OFFICE  CLASS  SUBCLASS  TRANSLATION (YES/NO)  J.L.  J.M.  J.N.  J.N.  J.O.  J.P.  J.Q.  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  J.R.  Monocydes, and Lymphocytes, and a Potent Agonist at CC Chemokine, a Chemoattractant for Neutrophils, Monocydes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205 (1997)  J.S.  Zhang et al., Differential Effects of Leukolactin-1 and Macrophage Inflammatiory Protein-1alpha on Neutrophils Mediated by CCR1. J. Immunol. 162:4938-4942 (1999)  J.T.  Zhu et al., Pulmonary expression of inleteukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production, J. Clin. Invest. 103:779-788 (1999)		J.D																	
J.G J.H J.H J.J J.J J.J J.J J.J J.J J.J J.J		J.E																	
J.H.  J.I.  J.J.  J.K.  FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS  FOREIGN PATENTS OR PUBLICATION  DOCUMENT PUBLICATION COUNTRY OR PATENT OFFICE CLASS SUBCLASS TRANSLATION (YES/NO)  J.L.  J.M.  J.M.  J.N.  J.N.  J.D.  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  J.R.  Youn et al., Molecular Cloning of Leukotactin-1: A Novel Human beta-Chemokine, a Chemoattractant for Neutrophils, Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205 (1997)  J.S.  Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1, J. Immunol. 162:4938-4942 (1999)  DATE CONSIDERED  J. J. Zhu et al., Pulmonary expression of interteukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and ectaxin production, J. Clin. Invest. 103:779-788 (1999)		J.F																	
J.I  J.J  J.K  FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS  FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS  TRANSLATION COUNTRY OR PATENT OFFICE CLASS SUBCLASS (YES/NO)  J.L  J.M  J.N  J.N  J.O  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  J.R  Youn et al., Molecular Cloning of Leukotactin-1: A Novel Human beta-Chemokine, a Chemoattractant for Neutrophils, Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3. J. Immunol. 159:5201-5205  J.S  Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1. J. Immunol. 162:4938-4942 (1999)  EXAMINER  DATE CONSIDERED  1/17/06		J.G													ļ				
J.J.  J.K.  DOCUMENT NUMBER  PUBLICATION COUNTRY OR PATENT OFFICE CLASS SUBCLASS TRANSLATION (YES/NO)  J.D.  J.D.  J.D.  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  J.R.  Youn et al., Molecular Cloning of Leukotactin-1: A Novel Human beta-Chemokine, a Chemoattractant for Neutrophils, Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205  J.S.  Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1, J. Immunol. 162:4938-4942 (1999)  D.T.  Zhu et al., Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103:779-788 (1999)  DATE CONSIDERED  J.17/06		J.H									ļ		_						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS    DOCUMENT NUMBER   PUBLICATION   COUNTRY OR PATENT OFFICE   CLASS   SUBCLASS   TRANSLATION (YES/NO)		J.I										·							
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS  DOCUMENT NUMBER PUBLICATION COUNTRY OR PATENT OFFICE CLASS SUBCLASS TRANSLATION (YES/NO)  J.L J.		J.J						┙						<u> </u>					
DOCUMENT NUMBER  PUBLICATION PATENT OFFICE  CLASS SUBCLASS  TRANSLATION (YES/NO)  J.M  J.N  J.O  J.P  J.Q  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  J.R  Youn et al., Molecular Cloning of Leukotactin-1: A Novel Human beta-Chemokine, a Chemoattractant for Neutrophils, Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205 (1997)  J.S  Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1. J. Immunol. 162:4938-4942 (1999)  J.T  Zhu et al., Pulmonary expression of interteukin-13 causes inflammation, mucus hypersecretion, subepithellal fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103:779-788 (1999)  DATE CONSIDERED		J.K								<u> </u>					<u> </u>		<u> </u>		
J.L  J.M  J.N  J.O  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  J.R  Youn et al., Molecular Cloning of Leukotactin-1: A Novel Human beta-Chemokine, a Chemoattractant for Neutrophils, Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205 (1997)  J.S  Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1. J. Immunol. 162:4938-4942 (1999)  J.T  Zhu et al., Pulmonary expression of interteukin-13 causes inflammation, mucus hypersecretion, subepithellal fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103:779-788 (1999)  DATE CONSIDERED						FO	REI	GN	PAT	ENTS OR PL	BLISHED	FOREIGN PA	ATENT A	PPLICATION	18				
J.N  J.O  J.P  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  J.R  Youn et al., Molecular Cloning of Leukotactin-1: A Novel Human beta-Chemokine, a Chemoattractant for Neutrophils, Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205 (1997)  J.S  Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1, J. Immunol. 162:4938-4942 (1999)  J.T  Zhu et al., Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithellal fibrosis, physiologic abnormalities, and eotaxin production, J. Clin. Invest. 103:779-788 (1999)  EXAMINER  DATE CONSIDERED									P							LASS			
J.N  J.O  J.P  J.Q  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  J.R  Youn et al., Molecular Cloning of Leukotactin-1: A Novel Human beta-Chemokine, a Chemoattractant for Neutrophils, Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205 (1997)  J.S  Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1, J. Immunol. 162:4938-4942 (1999)  J.T  Zhu et al., Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production, J. Clin. Invest. 103:779-788 (1999)  EXAMINER  DATE CONSIDERED		J.L											<u> </u>						
J.O  J.P  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  J.R  Youn et al., Molecular Cloning of Leukotactin-1: A Novel Human beta-Chemokine, a Chemoattractant for Neutrophils, Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205 (1997)  J.S  Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1. J. Immunol. 162:4938-4942 (1999)  J.T  Zhu et al., Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103:779-788 (1999)  DATE CONSIDERED		J.M										.,							
J.P  J.Q  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  J.R Youn et al., Molecular Cloning of Leukotactin-1: A Novel Human beta-Chemokine, a Chemoattractant for Neutrophils, Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205 (1997)  J.S Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1, J. Immunol. 162:4938-4942 (1999)  J.T Zhu et al., Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production, J. Clin. Invest. 103:779-788 (1999)  EXAMINER  DATE CONSIDERED		J.N																	
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  J.R Youn et al., Molecular Cloning of Leukotactin-1: A Novel Human beta-Chemokine, a Chemoattractant for Neutrophils, Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205 (1997)  J.S Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1, J. Immunol. 162:4938-4942 (1999)  J.T Zhu et al., Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production, J. Clin. Invest. 103:779-788 (1999)  EXAMINER  DATE CONSIDERED		J.O																	
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)  J.R Youn et al., Molecular Cloning of Leukotactin-1: A Novel Human beta-Chemokine, a Chemoattractant for Neutrophils, Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205 (1997)  J.S Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1, J. Immunol. 162:4938-4942 (1999)  J.T Zhu et al., Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production, J. Clin. Invest. 103:779-788 (1999)  EXAMINER  DATE CONSIDERED		J.P									_								
J.R Youn et al., Molecular Cloning of Leukotactin-1: A Novel Human beta-Chemokine, a Chemoattractant for Neutrophils, Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205 (1997)  J.S Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1, J. Immunol. 162:4938-4942 (1999)  J.T Zhu et al., Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production, J. Clin. Invest. 103:779-788 (1999)  EXAMINER  DATE CONSIDERED		J.Q								<del></del>							<del>-</del>		
Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205 (1997)  J.S Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1, J. Immunol. 162:4938-4942 (1999)  J.T Zhu et al., Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production, J. Clin. Invest. 103:779-788 (1999)  EXAMINER  DATE CONSIDERED																			
CCR1, J. Immunol. 162:4938-4942 (1999)  Zhu et al., Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production, J. Clin. Invest. 103:779-788 (1999)  EXAMINER  DATE CONSIDERED	M	J.R	Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3, J. Immunol. 159:5201-5205																
EXAMINER PATE CONSIDERED 1/17/06		J.S	Zhang et al., Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by														rophils Mediated by		
1/17/06	M	J.T	Zhu et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis,													helial fibrosis,			
	EXAMINER	INER BL.										DATE CONS	1/17/06						
Include a copy of this form with next communication to applicant.	EXAMINER:	Initial if c	tation	1 60	nsid	ere	d, wl	neth	er o	r not in confo	rmance. (	Draw line throu	gh citatio		<del></del>		nd not considered.		

Substitute Disclosure Form (PTO-1449)

<u>.</u>																	
·								<del></del>							11 (K) of 11		
SUBSTITUTE FORM PTO-1449 (MODIFIED)							U. P.	S. DEPARTM ATENT AND	IENT OF TRADEM	COMMERCE MARK OFFICE		ATTY.	DOCKET NO	). 	SERIAL NO. 10/752,659		
				FORMATION DISCLOSURE TATEMENT BY APPLICANT									CANT Iliot Rothenb	erg et	\		
(37 CFR 1.98	(L	Jse s	seve	eral s	heel	s if ne	ecessary)				FILING Januar	DATE y 7, 2004		GROUP Unknown			
<u>`                                    </u>			•					Ų.S.	PATENT	DOCUMENTS	3						
EXAMINER INITIAL		PATE	ENT	NUI	иве	R	ISSUE DATE		PATENTEE		CLASS		SUBCLASS		FILING DATE IF APPROPRIATE		
	к.а	П															
	к.в	$\sqcap$	$\top$	1		Γ											
	к.с	Ħ	$\top$	1	T	1											
	K.D	$\sqcap$	T	T	丁	1							_				
	K.E	17	1	T		T											
	K.F	$\Box$	1		1												
	K.G	П	寸	1													
	к.н	$\Box$		T		T											
	K.I			1													
	K.J			1		Τ								<u> </u>			
	к.к			1										<u> </u>			
				ı	FOR	EIGN	N PAT	ENTS OR PL	JBLISHE	D FOREIGN PA	A.	TENT A	PPLICATION	15			
		DOCUMENT NUMBER					P	UBLICATION DATE		COUNTRY OR PATENT OFFICE					_ASS	TRANSLATION (YES/NO)	
	K.L																
	к.м																
	K.N																
	к.о																
	K.P																
<del></del>	K.Q										_						
					ОТ	HER	DOC	UMENTS (Inc	duding A	uthor, Title, Dat	te	, Place	of Publication	n)			
M	K.R	Zimmermann et al., <u>CC Chemokine Receptor-3 Undergoes Prolonged Ligand-induced Internalization</u> , J. Biol. Chem. 274:12611-12618 (1999)															

K.R Zimmermann et al., CC Chemokine Receptor-3 Undergoes Prolonged Ligand-induced Internalization, J. Biol. Chem. 274:12611-12618 (1999)

K.S Zimmermann et al., Murine Eotaxin-2: A Constitutive Eosinophil Chemokine Induced by Allergen Challenge and II-4 Overexpression, J. Immunol. 165:5839-5846 (2000)

K.T Zimmermann et al., Molecular Analysis of CCR-3 Events in Eosinophilic Cells, J. Immunol. 164:1055-1064 (2000)

EXAMINER

H

DATE CONSIDERED

1/17/06